153 related articles for article (PubMed ID: 26874196)
1. Slow-binding inhibition of cholinesterases, pharmacological and toxicological relevance.
Masson P; Lushchekina SV
Arch Biochem Biophys; 2016 Mar; 593():60-8. PubMed ID: 26874196
[TBL] [Abstract][Full Text] [Related]
2. Slow-binding inhibitors of acetylcholinesterase of medical interest.
Lushchekina SV; Masson P
Neuropharmacology; 2020 Oct; 177():108236. PubMed ID: 32712274
[TBL] [Abstract][Full Text] [Related]
3. Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
Tommonaro G; García-Font N; Vitale RM; Pejin B; Iodice C; Cañadas S; Marco-Contelles J; Oset-Gasque MJ
Eur J Med Chem; 2016 Oct; 122():326-338. PubMed ID: 27376495
[TBL] [Abstract][Full Text] [Related]
4. Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment.
Kharlamova AD; Lushchekina SV; Petrov KA; Kots ED; Nachon F; Villard-Wandhammer M; Zueva IV; Krejci E; Reznik VS; Zobov VV; Nikolsky EE; Masson P
Biochem J; 2016 May; 473(9):1225-36. PubMed ID: 26929400
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterases and the fine line between poison and remedy.
Pope CN; Brimijoin S
Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent kinetic complexities in cholinesterase-catalyzed reactions.
Masson P
Biochemistry (Mosc); 2012 Oct; 77(10):1147-61. PubMed ID: 23157295
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics.
Makhaeva GF; Aksinenko AY; Sokolov VB; Serebryakova OG; Richardson RJ
Bioorg Med Chem Lett; 2009 Oct; 19(19):5528-30. PubMed ID: 19717305
[TBL] [Abstract][Full Text] [Related]
8. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
[TBL] [Abstract][Full Text] [Related]
9. Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning.
Saifina LF; Abdalla M; Gubaidullina LM; Zueva IV; Eltayb WA; El-Arabey AA; Kharlamova AD; Lenina OA; Semenov VE; Petrov KA
Eur J Med Chem; 2023 Jan; 246():114949. PubMed ID: 36462442
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cholinesterase inhibition by inorganic mercury.
Frasco MF; Colletier JP; Weik M; Carvalho F; Guilhermino L; Stojan J; Fournier D
FEBS J; 2007 Apr; 274(7):1849-61. PubMed ID: 17355286
[TBL] [Abstract][Full Text] [Related]
11. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
[TBL] [Abstract][Full Text] [Related]
12. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
Komloova M; Musilek K; Horova A; Holas O; Dohnal V; Gunn-Moore F; Kuca K
Bioorg Med Chem Lett; 2011 Apr; 21(8):2505-9. PubMed ID: 21397501
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
Musilek K; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K
Eur J Med Chem; 2011 Feb; 46(2):811-8. PubMed ID: 21236521
[TBL] [Abstract][Full Text] [Related]
14. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
[TBL] [Abstract][Full Text] [Related]
15. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease.
Venneri A; McGeown WJ; Shanks MF
Neuroreport; 2005 Feb; 16(2):107-10. PubMed ID: 15671856
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Więckowska A; Więckowski K; Bajda M; Brus B; Sałat K; Czerwińska P; Gobec S; Filipek B; Malawska B
Bioorg Med Chem; 2015 May; 23(10):2445-57. PubMed ID: 25868744
[TBL] [Abstract][Full Text] [Related]
17. Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles.
Samadi A; Marco-Contelles J; Soriano E; Alvarez-Pérez M; Chioua M; Romero A; González-Lafuente L; Gandía L; Roda JM; López MG; Villarroya M; García AG; Ríos Cde L
Bioorg Med Chem; 2010 Aug; 18(16):5861-72. PubMed ID: 20656495
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
Huang L; Luo Z; He F; Lu J; Li X
Bioorg Med Chem; 2010 Jun; 18(12):4475-84. PubMed ID: 20471843
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.
Luo Z; Liang L; Sheng J; Pang Y; Li J; Huang L; Li X
Bioorg Med Chem; 2014 Feb; 22(4):1355-61. PubMed ID: 24461494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
